The following is a copy of a press release issued by Cellectar BiosciencesPartnership Provides Long-Term Supply of...
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
read more
News
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM,...
Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates...
Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors
Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced...
Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity
Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June...
Registration for 2025 World Astatine Community Meeting Now Open
Radiopharmaceutical experts and researchers to gather June 19-20 in New OrleansNEW ORLEANS – May 12, 2025 – The...
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates